2015
DOI: 10.1097/j.pain.0000000000000228
|View full text |Cite
|
Sign up to set email alerts
|

Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0

Year Published

2015
2015
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 26 publications
(14 citation statements)
references
References 93 publications
(107 reference statements)
0
12
0
Order By: Relevance
“…However, although these drugs are supposed to have a very high specificity for a cell type or a surface receptor, there might still be some receptor expression in other cell types, resulting in controversial outcomes of different studies like for instance in the case of the L-AAA-induced astrocyte ablation ( Saffran and Crutcher, 1987 ; Khurgel et al, 1996 ). The same becomes true for microglia: although there are no controversial reports about the application of PLX3397 to induce myeloid cell death, it is already known that the drug might cross-react with some other receptor-kinases like, e.g., the platelet-derived growth factor receptor (PDGFR) making also other cells expressing those susceptible to cell death ( Cornelis et al, 2005 ; Chitu et al, 2012 ; Thompson et al, 2015 ). For NG2-glia there are until now no cell specific drugs available, probably due to the lack of a unique promising target receptor on those cells.…”
Section: Discussion and Outlookmentioning
confidence: 99%
“…However, although these drugs are supposed to have a very high specificity for a cell type or a surface receptor, there might still be some receptor expression in other cell types, resulting in controversial outcomes of different studies like for instance in the case of the L-AAA-induced astrocyte ablation ( Saffran and Crutcher, 1987 ; Khurgel et al, 1996 ). The same becomes true for microglia: although there are no controversial reports about the application of PLX3397 to induce myeloid cell death, it is already known that the drug might cross-react with some other receptor-kinases like, e.g., the platelet-derived growth factor receptor (PDGFR) making also other cells expressing those susceptible to cell death ( Cornelis et al, 2005 ; Chitu et al, 2012 ; Thompson et al, 2015 ). For NG2-glia there are until now no cell specific drugs available, probably due to the lack of a unique promising target receptor on those cells.…”
Section: Discussion and Outlookmentioning
confidence: 99%
“…PLX3397 (also known as Pexidartinib; MedChemExpress, NJ) inhibits the tyrosine protein kinase c‐Kit, CSF1R, and FMS‐related tyrosine kinase 3, resulting in substantial reductions in microglial population within the brain (Elmore et al, 2014; Rice et al, 2015; Spangenberg et al, 2016; Thompson et al, 2015). This compound was incorporated into standard rat chow at 1,200 mg/kg (TD.170153 formula, Envigo, Huntingdon, UK) to provide approximately 45 mg/kg of PLX3397 in the food.…”
Section: Methodsmentioning
confidence: 99%
“…Furthermore, the BBB remains intact after treatment, as assessed by Evans Blue straining [10]. However, this inhibitor is not specific for CSF-1R, as it also inhibits three other kinases: FLT3, PDGFR, and KIT [49,50]. In addition, systemic treatment with CSF-1R inhibitor leads to broad myelosuppression, impacting macrophages, HSCs, osteoclasts, and mast cells [51].…”
Section: Genetic Deletion Models In Micementioning
confidence: 97%